MicroPort® Attends OCC 2018

Shanghai, China – On May 31, Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") attended the 12th Oriental Congress of Cardiology ("OCC 2018") in Shanghai Expo Center and hosted a satellite meeting and a case contest. The OCC 2018 was hosted by Shanghai Medical Association and Chinese Society of Cardiology, focusing on the development and application of modern science in the field of cardiovascular diseases, while providing cardiologists a platform for academic exchange.
On June 1, MicroPort® hosted a satellite meeting, which was co-chaired by Professor Yundai Chen of Chinese PLA General Hospital, Professor Xuebo Liu of Shanghai Tongji Hospital, Professor Yangang Su of Zhongshan Hospital of Fudan University, Professor Yawei Xu of Shanghai Tenth People's Hospital, and Professor Zheng Zhang of the First Hospital of Lanzhou University. In the satellite meeting, Professor Bo Xu of Fuwai Hospital of Chinese Academy of Medical Sciences released the two-year clinical and imaging outcome of the FUTURE-I research, the First-In-Man ("FIM") study on Firesorb® Bioresorbable Sirolimus Target Eluting Coronary Scaffold System ("Firesorb®"). According to the result, the occurrence of the main endpoint in two years is zero, the occurrence of patient-oriented composite endpoint ("PoCE"), including death, myocardial infarction, and revascularization is 2.2%, and the occurrence of all-cause mortality, target vessel MI and stent thrombosis are all zero, which fully demonstrated the safety and efficacy of Firesorb®.
Professor Hui Gong of Jinshan Hospital of Fudan University delivered a report on "Physiological Pacing: New concept of the A2D mode". He pointed out, SafeR algorithm can realize A2D Physiological Pacing. The SafeR function of Rega™ Family Implantable Pacemakers developed by MicroPort Sorin CRM (Shanghai) Co., Ltd. ("MSC") can provide effective management for both SND and AVB patients by a more physiological therapy.
Professor Songhua Li of Shanghai Changhai Hospital explained in details the treatment strategies of using Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®") to treat diffuse and tortuous lesion. Professor Li said, Firehawk® shows excellent crossability in such lesion with low long-term thrombus rate. The outstanding clinical performance of Firehawk® has won high recognition among physicians and patients. This satellite meeting was live broadcasted via Dr. King studio, which attracted more than 500 audience to watch online. It provided opportunities for physicians in rural areas to learn more advanced technologies.
On June 2, Professor Bo Xu announced the primary endpoint data at 12 months and QCA angiography data at 13 months from its TARGET All-Comers ("TARGET AC") trial. The results of the TARGET AC trial demonstrated that vessels treated with the Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®") showed non-inferiority results when compared to vessels treated with the Xience family of drug eluting stents. Such results further demonstrated that Firehawk® achieves the same efficacy with one third dosage versus similar products.
The latest results of TARGET AC were released at EuroPCR 2018 held in May. As the first large-scale, high-quality randomized clinical study carried out in Europe by a Chinese medical device company, TARGET AC caught wide attention from domestic and overseas cardiologists, especially when the study meets the primary endpoint. Such favorable results once again strengthened the leadership of Firehawk® in the field of drug-eluting stent worldwide.